Literature DB >> 15120099

Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis.

Hélio A G Teive1, André R Troiano, Francisco M B Germiniani, Lineu C Werneck.   

Abstract

BACKGROUND: Drug-Induced Parkinsonism (DIP) represents the second leading cause of Parkinsonism (PK) in several countries. Flunarizine and cinnarizine are some of the most common drugs that cause DIP. This paper reviews the first description of Flunarizine and Cinnarizine-Induced Parkinsonism (FCIP), as well as the subsequent literature, emphasizing epidemiological, clinical and diagnostic aspects.
METHODS: We reviewed the literature on the subject, with special emphasis on the first description and the later definition of the clinical syndrome that results from chronic use of flunarizine and cinnarizine.
RESULTS: In 1984, De Melo-Souza reported the first description of flunarizine-induced PK in five patients. Other reports followed on FCIP, emphasizing the clinical features, which are symmetrical parkinsonism, and depression, affecting mainly elderly women.
CONCLUSIONS: Eighteen years after the original description, FCIP is a recognized condition with specific clinical features, and is the second most common cause of parkinsonism in many countries.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120099     DOI: 10.1016/j.parkreldis.2003.12.004

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  17 in total

Review 1.  Potentially inappropriate medications in the elderly: a comprehensive protocol.

Authors:  Suzana Mimica Matanović; Vera Vlahovic-Palcevski
Journal:  Eur J Clin Pharmacol       Date:  2012-02-24       Impact factor: 2.953

2.  L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza's syndrome.

Authors:  Upinder Kaur; Pritam Das; Indrajeet Singh Gambhir; Sankha Shubhra Chakrabarti
Journal:  Neurol Sci       Date:  2018-12-01       Impact factor: 3.307

3.  Fixed combination of cinnarizine and dimenhydrinate in the prophylactic therapy of vestibular migraine: an observational study.

Authors:  R Teggi; B Colombo; O Gatti; G Comi; M Bussi
Journal:  Neurol Sci       Date:  2015-06-03       Impact factor: 3.307

4.  Looks vestibular: irrational prescribing of antivertiginous drugs for older dizzy patients in general practice.

Authors:  Otto R Maarsingh; François G Schellevis; Henriëtte E van der Horst
Journal:  Br J Gen Pract       Date:  2012-10       Impact factor: 5.386

5.  Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study.

Authors:  Hsiu-Li Lin; Hsiu-Chen Lin; Yuan-Fu Tseng; Shih-Chang Chen; Chien-Yeh Hsu
Journal:  Eur J Clin Pharmacol       Date:  2016-12-16       Impact factor: 2.953

6.  Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES).

Authors:  Elan D Louis; Julián Benito-León; Félix Bermejo-Pareja
Journal:  Neuroepidemiology       Date:  2009-08-20       Impact factor: 3.282

Review 7.  Current Treatment Options: Vestibular Migraine.

Authors:  Clinton G Lauritsen; Michael J Marmura
Journal:  Curr Treat Options Neurol       Date:  2017-09-30       Impact factor: 3.598

8.  Modulation of visceral nociception, inflammation and gastric mucosal injury by cinnarizine.

Authors:  Omar M E Abdel-Salam
Journal:  Drug Target Insights       Date:  2007-02-12

9.  Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine.

Authors:  Kai-Ming Jhang; Jing-Yang Huang; Oswald Ndi Nfor; Yu-Chun Tung; Wen-Yuan Ku; Chun-Te Lee; Yung-Po Liaw
Journal:  Eur J Clin Pharmacol       Date:  2017-04-06       Impact factor: 2.953

10.  Amelioration of the haloperidol-induced memory impairment and brain oxidative stress by cinnarizine.

Authors:  Omar M E Abdel-Salam; Marwa El-Sayed El-Shamarka; Neveen A Salem; Aliaa E M K El-Mosallamy; Amany A Sleem
Journal:  EXCLI J       Date:  2012-08-27       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.